An Open-label, Biomarker Study of Arsenic Trioxide for the Treatment of Patients With Basal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2016
At a glance
- Drugs Arsenic trioxide (Primary)
- Indications Basal cell cancer
- Focus Biomarker; Pharmacodynamics
- 17 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 17 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Apr 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.